Home › Free Stock Grades › PLX
Protalix BioTherapeutics, Inc. (PLX) Stock Grade
PLX · Healthcare
B-
Market Cap
$141.4M
P/E Ratio
8.3
Revenue Growth (YoY)
-1.2%
Net Margin
-12.5%
Return on Equity
—
Dividend Yield
None
About Protalix BioTherapeutics, Inc.'s fundamentals
Protalix BioTherapeutics is a small-cap biotechnology company with a market capitalization of $141.4 million that is currently unprofitable, posting a net margin of -12.5% and reporting a net loss in its latest annual statement. The company's revenue declined 1.2% year-over-year, indicating contraction rather than growth during this period. With a P/E ratio of 8.3, the valuation metric is limited in relevance given the company's negative earnings, and the company does not pay a dividend to shareholders.